Form 4 for CYTK CYTOKINETICS INC
Accepted 2025-03-18 00:00:00 ET · period of report 2025-03-14 · accession 0001127602-25-009760 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-03-18 | 2025-03-14 | CYTK | Malik Fady Ibraham | EVP Research, Development | A - Grant | $0.00 | +39.5K | 144.8K | +37% | $0 |
| DM | 2025-03-18 | 2025-03-14 | CYTK | Malik Fady Ibraham | EVP Research, Development | A - Grant | $0.00 | +60.8K | 2,293 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-14 | A | A | 39,450 | $0.00 | 144,844 | D | — | — | |
| 2 | Derivative | Non-Qualified Stock Option (Right to Buy) | 2025-03-14 | A | A | 58,465 | $0.00 | 58,465 | D | $44.36 · 2025-04-14 to 2035-03-13 | 58,465 Common Stock | |
| 3 | Derivative | Incentive Stock Option (Right to Buy) | 2025-03-14 | A | A | 2,293 | $0.00 | 2,293 | D | $44.36 · 2025-04-14 to 2035-03-13 | 2,293 Common Stock |